Erica Slaughter, MS

A novel bioequivalent of dimethyl fumarate (Tecfidera) may soon be offering another treatment option for patients with multiple sclerosis.

For patients in the HSCT group, disease-modifying therapies use was discontinued, followed by variable washout periods before admission for HSCT.

Acrolein levels were significantly elevated in urine and serum in patients with multiple sclerosis compared to healthy controls.

Ocrelizumab demonstrated superiority to or comparability with 14 other disease-modifying therapies currently approved by the European Medicines Agency.